ArticleWorld journal of radiology2017
Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma.
Article in World journal of radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07494838 (IMAGES), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
IMAGES: Identifying Metabolic Imaging Association With Genicular Artery Embolization Success
Who cites it
19 citing papers in PubMed.
- Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial).Cardiovascular and interventional radiology · 2024Trial
- Temperature-sensitive liquid embolic agent loaded with Lobaplatin in the TACE procedure for rabbit VX2 liver tumor.Scientific reports · 2026Article
- Efficacy and safety of raltitrexed-eluting CalliSpheresTherapeutic advances in medical oncology · 2024Article
- Article
- Article
- Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads.Cardiovascular and interventional radiology · 2022Article
- Effect of bead size and doxorubicin loading on tumor cellular injury after transarterial embolization and chemoembolization in a rat model of hepatocellular carcinoma.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation.Cardiovascular and interventional radiology · 2021Article
- Transarterial Chemoembolization of Hepatocellular Carcinoma with Oncozene Microspheres: An Initial, Short-Term Clinical Experience-A Retrospective, Matched, Comparison Study.Life (Basel, Switzerland) · 2021Article
- The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment.Scientific reports · 2021Article
- Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm.Life (Basel, Switzerland) · 2021Article
- Interventional radiology for liver diseases.European radiology · 2021Article
- Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres.Journal of cancer research and clinical oncology · 2021Article
- Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.Drug delivery · 2020Article
- Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety.Diagnostic and interventional radiology (Ankara, Turkey) · 2020Article
- Drug-eluting beads-transcatheter arterial chemoembolization with or without iodine-125 treatment is effective and tolerable in treating advanced non-small cell lung cancer patients: a pilot study.Translational cancer research · 2020Article
- Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study.Journal of the Belgian Society of Radiology · 2019Article
- Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.World journal of gastroenterology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment.
methodsDrug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging. Eleven out of the 48 treated patients treated progressed on to receive liver orthotopic transplantation (OLT). This allowed for histological analysis on the treated explanted nodules.
resultsDEB-TACE with 40 μm showed a good safety profile without major complications or 30-d mortality. The objective response rate of treated tumors was 72.6% and 26.7% according to mRECIST and RECIST respectively. Histological examination in 11 patients assigned to OLT showed a necrosis degree > 90% in 78.6% of cases. The overall time to progression was 13 mo (11-21).
conclusionDEB-TACE with 40 μm particles is an effective treatment for the treatment of HCC in early-intermediate patients (Barcelona Clinic Liver Cancer stage A/B) with a good safety profile and good results in term of objective response rate and necrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.